Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study

Fabrizio Cantini; Laura Niccoli; Carlotta Nannini; Daniela Matarrese; Massimo Edoardo Di Natale; Pamela Lotti; Donatella Aquilini; Giancarlo Landini; Barbara Cimolato; Massimo Antonio Di Pietro; Michele Trezzi; Paolo Stobbione; Gabriele Frausini; Assunta Navarra; Emanuele Nicastri; Giovanni Sotgiu; Delia Goletti

doi:10.1016/j.jinf.2020.06.052

Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study

J Infect. 2020 Oct;81(4):647-679. doi: 10.1016/j.jinf.2020.06.052. Epub 2020 Jun 24.

Authors

Fabrizio Cantini¹, Laura Niccoli², Carlotta Nannini², Daniela Matarrese³, Massimo Edoardo Di Natale⁴, Pamela Lotti⁵, Donatella Aquilini⁶, Giancarlo Landini⁷, Barbara Cimolato⁸, Massimo Antonio Di Pietro⁹, Michele Trezzi¹⁰, Paolo Stobbione¹¹, Gabriele Frausini¹², Assunta Navarra¹³, Emanuele Nicastri¹⁴, Giovanni Sotgiu¹⁵, Delia Goletti¹⁶

Affiliations

¹ Rheumatology department, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: fbrzcantini@gmail.com.
² Rheumatology department, Azienda USL Toscana Centro, Hospital of Prato, Italy.
³ Sanitary Direction, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: daniela.matarrese@uslcentro.toscana.it.
⁴ II Division of Internal Medicine, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: massimoedoardo.dinatale@uslcentro.toscana.it.
⁵ II Division of Internal Medicine, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: pamela.lotti@uslcentro.toscana.it.
⁶ Division of Infectious Diseases, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: donatella.aquilini@uslcentro.toscana.it.
⁷ Department of Medical Specialties, Division of Internal Medicine, Azienda USL Toscana Centro, S.Maria Nuova Hospital, Florence, Italy. Electronic address: giancarlo.landini@uslcentro.toscana.it.
⁸ Department of Medical Specialties, Division of Internal Medicine, Azienda USL Toscana Centro, S.Maria Nuova Hospital, Florence, Italy. Electronic address: barbara.cimolato@uslcentro.toscana.it.
⁹ Division of Infectious Diseases, Azienda USL Toscana Centro, Hospital of Pistoia, Italy. Electronic address: massimoantonio.dipietro@uslcentro.toscana.it.
¹⁰ Division of Infectious Diseases, Azienda USL Toscana Centro, Hospital of Pistoia, Italy. Electronic address: michele.trezzi@uslcentro.toscana.it.
¹¹ Rheumatology Unit, AO SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy. Electronic address: pstobbione@ospedale.al.it.
¹² Division of Internal Medicine, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Fano-Pesaro, Italy. Electronic address: gabriele.frausini@ospedalimarchenord.it.
¹³ Clinical epidemiology Unit, National Institute for Infectious Diseases, Lazzaro Spallanzani, Rome, Italy. Electronic address: assunta.navarra@inmi.it.
¹⁴ Clinical Division of Infectious Diseases, National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy. Electronic address: emanuele.nicastri@inmi.it.
¹⁵ Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy. Electronic address: gsotgiu@uniss.it.
¹⁶ Translational Research Unit, Department of Epidemiology and Preclinical Research, "L. Spallanzani" National Institute for Infectious Diseases (INMI), IRCCS, Rome, Italy. Electronic address: delia.goletti@inmi.it.

Abstract

•
Baricitinib, an anti-JAK1/JAK2, reduces cytokine release and SARS-Co-V2 entry.
•
In a retrospective multicenter study baricitinib reduces COVID-19 mortality rate.
•
Baricitinib reduces intensive care unit admissions of COVID-19 pneumonia.
•
Baricitinb reduces SARS-CoV-2 viral burden detected by nasopharyngeal swab.
•
Baricitinib used for 2 weeks was not associated with serious adverse events.

Keywords: Baricitinib; COVID-19; JAK1/2; Pneumonia; Retrospective study; SARS-Co-V2.

Publication types

Letter
Comment

MeSH terms

Azetidines
Betacoronavirus
COVID-19
Coronavirus Infections*
Humans
Pandemics*
Pilot Projects
Pneumonia, Viral*
Purines
Pyrazoles
SARS-CoV-2
Sulfonamides

Substances

Azetidines
Purines
Pyrazoles
Sulfonamides
baricitinib